南京伟思医疗科技股份有限公司

Group 1 - The company held its fourth Supervisory Board meeting on August 27, 2025, which complied with relevant laws and regulations [1] - The Supervisory Board unanimously approved the 2025 semi-annual report, confirming its compliance with legal requirements and accuracy [2][3] - The Supervisory Board also approved a special report on the use of raised funds, affirming that the funds were stored and used in accordance with regulations [4][5] Group 2 - The company approved the use of temporarily idle self-owned funds to purchase financial products, with a limit of up to RMB 1.05 billion within 12 months [6][7] - The decision to cancel the Supervisory Board and amend the Articles of Association was made to improve corporate governance [8][10] - The company plans to revise internal governance systems to enhance operational standards [11][12] Group 3 - The Board of Directors held its fifth meeting on August 27, 2025, with all members present, confirming compliance with legal and regulatory requirements [16] - The Board unanimously approved the semi-annual report and the special report on the use of raised funds, similar to the Supervisory Board's decisions [18][19] - The Board agreed to use idle funds for financial products, with the same investment limit and conditions as approved by the Supervisory Board [20][22] Group 4 - The Board proposed to elect a new independent director to replace the outgoing director, with the election scheduled for the upcoming shareholder meeting [23][25] - The Board also approved the cancellation of the Supervisory Board, with the responsibilities to be transferred to the Audit Committee [26][28] - A shareholder meeting is scheduled for September 15, 2025, to discuss various proposals [31][32] Group 5 - The company announced a half-year performance briefing scheduled for September 30, 2025, to discuss the semi-annual results and address investor inquiries [77][78] - The briefing will be conducted online, allowing for interactive communication with investors [79][81]